XTLB (XTL Biopharmaceuticals) Research & Development: $0.11 Mil (TTM As of Jun. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
24 GF Score
Price $2.57
! 2 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Research & Development?

XTL Biopharmaceuticals XTLB -8.01% 24 Research & Development is $0.11 Mil as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. XTL Biopharmaceuticals's Research & Development for the six months ended in Jun. 2025 was $0.02 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was $0.11 Mil.

XTL Biopharmaceuticals  (NAS:XTLB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

XTL Biopharmaceuticals Research & Development Related Terms

XTL Biopharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Research & Development Chart

XTL Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.03 0.03 0.03 0.10

XTL Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.09 0.02
XTLB
24GF Score
XTL Biopharmaceuticals Ltd XTLB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.11 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Research & Development of $0.11 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Research & Development too high?
XTL Biopharmaceuticals' current Research & Development is $0.11 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Research & Development compare to VRTX and REGN?
XTL Biopharmaceuticals' Research & Development of $0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Research & Development is $0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Research & Development of $0.11 Mil. The current Research & Development is $0.11 Mil. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Research & Development is $0.11 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score

Get the complete analysis for XTLB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price